Team Gleason has expanded its collaboration with Stentrode developer Synchron to help teach people about brain-computer ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the ...

This content is sponsored by Mitsubishi Tanabe Pharma America, Inc. (MTPA) and is intended for US audiences only. Any other ...

The number of ALS cases in the U.S. is expected to increase by over 10% by 2030, as compared with 2022 prevalence rates, per ...

Neurosense entered a binding term sheet with a global pharmaceutical company to advance development and commercialization of ...

News stories about clinical trials testing potential treatments were among the top 10 most-read articles on ALS News Today in ...

A Phase 1 trial testing RAG-17, a potential ALS therapy for people carrying SOD1 mutations, has dosed its first participant.

The creatinine-to-cystatin C ratio may indicate the risk of developing amyotrophic lateral sclerosis, a large-scale database ...

Despite the lower ALS risk, heart and metabolism problems are tied to faster disease progression and worse survival in the ...

In her husband's nearly 15 years of living with ALS, columnist Kristin Neva sees pre- and post-diagnosis papers as a bittersweet treasure.

When Dagmar Munn was diagnosed with ALS at the age of 59 in 2010, she tapped into her nearly 30 years of professional health and wellness experience. She not only follows her own advice but also ...